tirzepatide fda approved confirms shortage is still over, gives compounders a grace period Tirzepatide FDA approved for sleep

However, its also prescribed off-label to help support meaningful weight loss

Those in the trial that did experience negative side effects did so at the same rate and consistency as those previously reported for injectable GLP-1 drugs and Eli Lilly said it "was consistent." The drugmaker said the most commonly reported negative side effects were mild to moderate gastrointestinal-related symptoms, such as nausea, constipation, indigestion, diarrhea and vomiting

Long-Term Risks of Repeated Overdosing Intentionally or accidentally taking higher-than-prescribed doses repeatedly can cause lasting damage to your gastrointestinal system

The relationship between measures of obesity and atherogenic lipids among Nigerians with hypertension

For women, rapid fat loss can shift the estrogen-to-androgen ratio

By 24 months, the proportion of patients with ongoing papilledema was lower in the tirzepatide group (RR 0.32, 95% CI 0.1890.542)